Compile Data Set for Download or QSAR
Report error Found 41 of ic50 data for polymerid = 8875
TargetEgl nine homolog 1 [179-426](Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM400041(USRE47437, Example {[5-(3-Cyanophenyl)-3-hydroxypy...)
Affinity DataIC50: 190nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetEgl nine homolog 1 [179-426](Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107703(US8722895, 9: {[5-(4-Chlorophenyl)-3-hydroxypyridi...)
Affinity DataIC50: 240nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetEgl nine homolog 1 [179-426](Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107708(US8722895, 14: {[5-(4-Chlorophenyl)-3-hydroxypyrid...)
Affinity DataIC50: 300nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetEgl nine homolog 1 [179-426](Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107717(US8722895, 23: ({3-Hydroxy-5-[3-(pyrrolidine-1- ca...)
Affinity DataIC50: 300nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetEgl nine homolog 1 [179-426](Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM301825(US9598370, Example 00149 | USRE47437, Example ({3-...)
Affinity DataIC50: 400nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetEgl nine homolog 1 [179-426](Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107704(US8598210, Table XV, 11 | US8598210, 119 | US87228...)
Affinity DataIC50: 410nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetEgl nine homolog 1 [179-426](Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107707(US8722895, 13: {[5-(4-Isopropylphenyl)-3-hydroxypy...)
Affinity DataIC50: 440nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetEgl nine homolog 1 [179-426](Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107698(US8722895, 4: [(3-Hydroxy-5-(4-methylphenyl)pyridi...)
Affinity DataIC50: 650nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetEgl nine homolog 1 [179-426](Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107704(US8598210, Table XV, 11 | US8598210, 119 | US87228...)
Affinity DataIC50: 1.10E+3nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetEgl nine homolog 1 [179-426](Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107706(US8722895, 12: {[5-(2-Chlorophenyl)-3-hydroxypyrid...)
Affinity DataIC50: 1.10E+3nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetEgl nine homolog 1 [179-426](Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM102350(US8536181, F3 | US9278930, F3 | US10562854, No. F3)
Affinity DataIC50: 1.20E+3nMpH: 7.5 T: 2°CAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetEgl nine homolog 1 [179-426](Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107711(US8722895, 17: 5-(3-Chlorophenyl)-N-(2-methylamino...)
Affinity DataIC50: 1.20E+3nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetEgl nine homolog 1 [179-426](Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107709(US8722895, 15: {[5-(4-Isopropoxyphenyl)-3- hydroxy...)
Affinity DataIC50: 1.60E+3nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetEgl nine homolog 1 [179-426](Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107710(US8722895, 16: {[5-(2-Methyl-5-chlorophenyl)-3- hy...)
Affinity DataIC50: 2.50E+3nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetEgl nine homolog 1 [179-426](Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107716(US8722895, 22: ({3-Hydroxy-5-[3-(pyrrolidine-1-car...)
Affinity DataIC50: 2.50E+3nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetEgl nine homolog 1 [179-426](Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM301820(US9598370, Example 00144 | USRE47437, Example ({3-...)
Affinity DataIC50: 2.60E+3nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetEgl nine homolog 1 [179-426](Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107695(US8722895, 1: {[5-(3-chloro-phenyl)-3-hydroxy-pyri...)
Affinity DataIC50: 2.80E+3nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetEgl nine homolog 1 [179-426](Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107696(US8722895, 2: {[5-(4-Chloro-phenyl)-3-hydroxy-pyri...)
Affinity DataIC50: 3.70E+3nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetEgl nine homolog 1 [179-426](Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107700(US8722895, 6: [(3-Hydroxy-5-(4-methylphenyl)-pyrid...)
Affinity DataIC50: 4.10E+3nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetEgl nine homolog 1 [179-426](Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM102345(US8536181, D10 | US9278930, D10 | US10562854, No. ...)
Affinity DataIC50: 4.40E+3nMpH: 7.5 T: 2°CAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetEgl nine homolog 1 [179-426](Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM102351(US8536181, F2 | US9278930, F2 | US10562854, No. F2)
Affinity DataIC50: 5.00E+3nMpH: 7.5 T: 2°CAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetEgl nine homolog 1 [179-426](Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM301819(US9598370, Example 00143 | USRE47437, Example {[5-...)
Affinity DataIC50: 5.10E+3nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetEgl nine homolog 1 [179-426](Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM301787(US9598370, Example 00128 | USRE47437, Example {[5-...)
Affinity DataIC50: 5.80E+3nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetEgl nine homolog 1 [179-426](Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107701(US8722895, 7: {[5-(2-Chloro-phenyl)-3-hydroxy-pyri...)
Affinity DataIC50: 6.80E+3nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetEgl nine homolog 1 [179-426](Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM126621(US8778412, B5 | US9278930, B5 | US10562854, No. B5)
Affinity DataIC50: 9.00E+3nMpH: 7.5 T: 2°CAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetEgl nine homolog 1 [179-426](Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107719(US8722895, 25: ({5-[3-(cyclopropanecarbonyl-amino)...)
Affinity DataIC50: 9.20E+3nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetEgl nine homolog 1 [179-426](Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM102341(US8536181, B14 | US9278930, B14 | US10562854, No. ...)
Affinity DataIC50: 1.10E+4nMpH: 7.5 T: 2°CAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetEgl nine homolog 1 [179-426](Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM102336(US8536181, C17 | US9278930, C17 | US10562854, No. ...)
Affinity DataIC50: 1.10E+4nMpH: 7.5 T: 2°CAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetEgl nine homolog 1 [179-426](Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107715(US8722895, 21: {[5-(3-Carbamoyl-phenyl)-3-hydroxy-...)
Affinity DataIC50: 1.12E+4nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetEgl nine homolog 1 [179-426](Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM102337(US8536181, C35 | US9278930, C35 | US10562854, No. ...)
Affinity DataIC50: 1.20E+4nMpH: 7.5 T: 2°CAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetEgl nine homolog 1 [179-426](Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM102347(US8536181, C1 | US9278930, C1 | US10562854, No. C1)
Affinity DataIC50: 1.20E+4nMpH: 7.5 T: 2°CAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetEgl nine homolog 1 [179-426](Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM102346(US8536181, D14 | US9278930, D14 | US10562854, No. ...)
Affinity DataIC50: 1.20E+4nMpH: 7.5 T: 2°CAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetEgl nine homolog 1 [179-426](Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM102342(US8536181, C19 | US9278930, C19 | US10562854, No. ...)
Affinity DataIC50: 1.20E+4nMpH: 7.5 T: 2°CAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetEgl nine homolog 1 [179-426](Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM102338(US8536181, C14 | US9278930, C14 | US10562854, No. ...)
Affinity DataIC50: 1.20E+4nMpH: 7.5 T: 2°CAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetEgl nine homolog 1 [179-426](Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM102348(US8536181, A41 | US9278930, A41 | US10562854, No. ...)
Affinity DataIC50: 1.40E+4nMpH: 7.5 T: 2°CAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In DepthDetails
US Patent

TargetEgl nine homolog 1 [179-426](Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM102340(US8536181, C33 | US9278930, C33 | US10562854, No. ...)
Affinity DataIC50: 1.60E+4nMpH: 7.5 T: 2°CAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetEgl nine homolog 1 [179-426](Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM102343(US8536181, B9 | US9278930, B9 | US10562854, No. B9)
Affinity DataIC50: 1.70E+4nMpH: 7.5 T: 2°CAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetEgl nine homolog 1 [179-426](Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM102344(US8536181, A18 | US9278930, A18 | US10562854, No. ...)
Affinity DataIC50: 1.80E+4nMpH: 7.5 T: 2°CAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetEgl nine homolog 1 [179-426](Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM107699(US8722895, 5: [(3-Hydroxy-4'-methyl-biphenyl-4...)
Affinity DataIC50: 2.00E+4nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetEgl nine homolog 1 [179-426](Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM102349(US8536181, E33 | US9278930, E33 | US10562854, No. ...)
Affinity DataIC50: 2.10E+4nMpH: 7.5 T: 2°CAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails
US Patent

TargetEgl nine homolog 1 [179-426](Human)
Akebia Therapeutics

US Patent
LigandPNGBDBM301799(US9598370, Example 00133 | USRE47437, Example {[5-...)
Affinity DataIC50: 9.90E+4nMAssay Description:The EGLN-1 (or EGLN-3) enzyme activity is determined using mass spectrometry (matrix-assisted laser desorption ionization, time-of-flight MS, MALDI-T...More data for this Ligand-Target Pair
In DepthDetails
US Patent